Tag: Braf inhibitor

Approximately 50% of melanoma patients have a BRAF V600 protein kinase mutation, a target for specific therapies [1.2.1]. For these patients, understanding 'How much does vemurafenib cost in the US?' is a critical part of managing their treatment journey and financial planning.

Over 50% of melanomas harbor a BRAF mutation, and treatments like dabrafenib, sometimes referred to confusingly as a 'dab tablet', have revolutionized therapy. The term 'dab tablet' is ambiguous and can refer to different medications, but it is often confused with dabrafenib, a potent targeted cancer drug. For clarity, we will focus on the oncology medication, dabrafenib, which requires a specific genetic mutation to be effective.

According to the American Cancer Society, about half of all melanomas have changes in the BRAF gene. A BRAF inhibitor is a targeted cancer drug that blocks the activity of the mutated BRAF protein, helping to stop cancer cells from growing and dividing uncontrollably.